ProQR Therapeutics BV

ProQR Therapeutics N.V. is a clinical-stage biotechnology company focused on discovering and developing novel therapeutic medicines. It is developing an RNA editing platform using its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead candidate, AX-0810, targets the Na+-taurocholate cotransporting polypeptide (NTCP) for cholestatic diseases. The company also develops AX-2402 for Rett syndrome, AX-2911 for metabolic dysfunction-associated steatohepatitis, and AX-1412 for cardiovascular diseases. It has a research and collaboration agreement with Eli Lilly and Company for genetic disorders of the liver and nervous system. Incorporated in 2012, ProQR is headquartered in Leiden, the Netherlands.